Reactomix SL is a biotech company focused on identifying patterns of changes in the physiology and / or pathology of cell and tissues in any species. Its main focus is to map the reactome of cells (biochemical reactions catalyzed) composed of signaling pathways and metabolic routes.
Reactomix builds upon a multiplexed proprietary platform to identify up to +3000 enzymes thus providing a powerful measure of the phenotype in a normal or treated cell or tissue.The simultaneous detection and quantitation of multiple biomarkers is now possible facilitating our understanding of the links between structure and function. The exploration of network biomarkers on a systems approach permits linking them to genomic, proteomic and transcriptomic data on a highly efficient way.
Reactomix was founded in 2011 to fully develop and commercialize the technology under an exclusive worldwide license granted by the Spanish National Research Council (CSIC) and the German Helmholtz-Zentrum für Infektionsforschung GmbH.